The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

August 02, 2021

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

August 02, 2021

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

July 29, 2021

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

July 29, 2021

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

July 20, 2021

Sairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.

July 19, 2021

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.

July 15, 2021

The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.

July 13, 2021

Prithviraj Bose, MD, discusses data with pelabresib from the MANIFEST trial and future research directions for BET inhibition in patients with myelofibrosis.

July 13, 2021

Richard Gorlick, MD, expands on the process of identifying these novel targets in osteosarcoma and the clinical implications of this research for these patients.

July 13, 2021

Naveen Pemmaraju, MD, discusses approaches to adequately manage symptoms experienced by patients with myelofibrosis, challenges faced with defining disease progression, and strategies for when to initiate or delay treatment.

June 24, 2021

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

June 23, 2021

The University of Texas MD Anderson Cancer Center is pursuing several novel approaches, including viro-immunotherapy and genetically engineered natural killer cells to treat patients with glioblastoma, while also conducting tumor analysis to better comprehend the disease.

June 17, 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.

June 14, 2021

Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.

June 10, 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

June 10, 2021

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.

June 09, 2021

Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.

June 05, 2021

Sotorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated non–small cell lung cancer.

June 04, 2021

The efficacy demonstrated with combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

June 02, 2021

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.